Effects of Nicotinamide Riboside on Metabolism and Vascular Function
1 other identifier
interventional
16
1 country
1
Brief Summary
The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2018
CompletedFirst Submitted
Initial submission to the registry
April 10, 2018
CompletedFirst Posted
Study publicly available on registry
April 18, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedSeptember 25, 2020
September 1, 2020
1.8 years
April 10, 2018
September 23, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
NAD+
Blood and peripheral blood mononuclear cell (PBMC) levels
7 days
Secondary Outcomes (3)
Vasodilatory responsiveness
7 days
Lipdemia
7 days
Oxidative stress and inflammation
7 days
Study Arms (2)
Nicotinamide Riboside Chloride (Niagen)
EXPERIMENTAL7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
Placebo
PLACEBO COMPARATOR7 days of placebo supplementation (2/day)
Interventions
250 mg capsules 2x/day for 7 days
Eligibility Criteria
You may qualify if:
- Age 18 to 35 (young) and 60 to 75 (older)
- Normo- or pre-hypertensive (blood pressure \<140/90 mmHg)
- Non-smokers
- Able to give informed consent and participate in all laboratory visits
You may not qualify if:
- Currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers)
- Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases
- Food allergies to egg, milk, soy or wheat
- Women who are pregnant or planning to become pregnant during the course of the study,
- Pacemaker or other implanted device
- Unwilling to participate in the experimental protocol or blood draws will be excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Iowa State University
Ames, Iowa, 50011, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rudy Valentine, PhD
Iowa State University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- I single investigator will be responsible for blinding. All researchers involved in collection and evaluation of data will remain blinded to treatments.
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 10, 2018
First Posted
April 18, 2018
Study Start
February 1, 2018
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
September 25, 2020
Record last verified: 2020-09
Data Sharing
- IPD Sharing
- Will not share